Session Chair: Max Cummings, Johnson & Johnson
Monday, 09 February 2015, from 14:00 to 17:00
SUMMARY
Showcase the use of structure based drug design in overcoming ADME-related challenges in drug discovery, foster discussion of any areas of perceived low-hanging fruit for the application of SBDD to ADME issues.
Max Cummings is a Computational Chemist at Janssen R&D, working on drug discovery in various therapeutic areas.
He earned his Ph.D. in Biochemistry under the supervision of Randy J. Read at the University of Alberta.
Inhibition of the hERG potassium channel is responsible for remarkably dangerous cardiac side effects of drugs that can eventually lead to the so‐called drug-induced long-QT syndrome (LQTS).
Long residence times gained interest in the pharmaceutical industry with two main drivers. Firstly, to overcome a poor PK profile. Secondly, to keep exposures as low as possible to improve the safety profile of the IND/NME.
Structures of PXR activators bound to the PXR ligand-binding domain offer an opportunity to apply structure-based methods to understand and mitigate compound-mediated induction of metabolic genes, potentially improving the metabolic profile ...
In this presentation we will describe recent developments to a method for predicting Cytochrome P450 metabolism that combines quantum mechanical (QM) simulations to estimate the reactivity of potential sites of metabolism on a compound with a ...
One needs three things to successfully use predictions of off-target activities in the drug-discovery process: Consistent assays of the relevant activities, preferably with high throughput, A software infrastructure to generate, validate, and publish QSAR models...
